OPKO Health Files 13D/A Amendment for GeneDx Holdings

TL;DR

OPKO Health updated its 13D filing on GeneDx Holdings, signaling changes in their stake.

AI Summary

OPKO Health, Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of GeneDx Holdings Corp. as of November 20, 2024. The filing details OPKO Health's holdings and intentions regarding GeneDx, a company formerly known as Sema4 Holdings Corp. and CM Life Sciences, Inc.

Why It Matters

This filing provides insight into the evolving ownership structure and potential strategic moves by OPKO Health concerning GeneDx Holdings, which could impact the market for GeneDx's securities.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can signal shifts in control or strategy, potentially leading to price volatility.

Key Players & Entities

• OPKO HEALTH, INC. (company) — Filing party and beneficial owner
• GeneDx Holdings Corp. (company) — Subject company
• Sema4 Holdings Corp. (company) — Former name of GeneDx Holdings Corp.
• CM Life Sciences, Inc. (company) — Former name of GeneDx Holdings Corp.

FAQ

Key Financial Figures

• $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $68.20 — the open market at prices ranging from $68.20 to $82.00 per share for an aggregate sa
• $82.00 — market at prices ranging from $68.20 to $82.00 per share for an aggregate sale price o
• $28,254,209 — n aggregate sale price of approximately $28,254,209. ITEM 5. Interest in Securities of
• $61,105,000 — n aggregate sale price of approximately $61,105,000. Sales of GeneDx Common Stock prior to

Filing Documents

• opk20241118_sc13da.htm (SC 13D/A) — 63KB
• 0001437749-24-035895.txt ( ) — 65KB

is amended by adding the following paragraph to the end of the item

Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between November 11, 2024 and November 20, 2024, OPKO sold a total of 375,833 shares of GeneDx Common Stock on the open market at prices ranging from $68.20 to $82.00 per share for an aggregate sale price of approximately $28,254,209. ITEM 5. Interest in Securities of the Issuer.

is deleted in its entirety and replaced with the following text

Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 1,370,841 4.99% ______________ (1) Based on 27,471,397shares of GeneDx Common Stock of the Issuer outstanding on October 22, 2024, as set forth in the Issuer's Form 10-Q filed with the SEC on October 29, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 9, OPKO sold a total of 800,833 shares of GeneDx Common Stock on the open market at prices ranging from $68.20 to $82.00 per share for an aggregate sale price of approximately $61,105,000. Sales of GeneDx Common Stock prior to November 11, 2024 were previously reported in Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, and Amendment No.8. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Sale Price Weighted Price Per Share 11/4/24 25,000 $ 1,902,415 $ 76.0966 11/5/24 75,000 $ 5,699,171 $ 75,9889 11/6/24 150,000 $ 11,510,776 $ 76.7385 11/7/24 50,000 $ 3,861,068 $ 77.2214 11/8/24 125,000 * $ 9,877,361 $ 79.0189 11/11/24 100,000 $ 7,576,946 $ 75.7695 11/13/24 125,000 $ 10,020,291 $ 80.1623 11/18/24 50,000 $ 3,586,620 $ 71.7324 11/19/24 40,833 $ 2,913,787 $ 71.3586 11/20/24 60,000 $ 4,156,566 $ 69.2761 CUSIP No. 81663L200 Schedule 13D PAGE 4 of 5 * Amendment No.8 erroneously reported 10,000 shares sold on November 8, 2024, which resulted in the incorrect aggregate number of shares reported purcha

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: November 20, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration

View Full Filing

View this SC 13D/A filing on SEC EDGAR